Scott J. Rodig
Brigham and Women's Hospital · 1,578 works · 78,060 citations · h-index 130
Top works
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- Adaptive immunity maintains occult cancer in an equilibrium state
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- An immunogenic personal neoantigen vaccine for patients with melanoma
- Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
- Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies